PL3179982T3 - Sposób zwiększenia biodostępności i/lub przedłużenia działania oftalmicznego leku - Google Patents

Sposób zwiększenia biodostępności i/lub przedłużenia działania oftalmicznego leku

Info

Publication number
PL3179982T3
PL3179982T3 PL15827671.7T PL15827671T PL3179982T3 PL 3179982 T3 PL3179982 T3 PL 3179982T3 PL 15827671 T PL15827671 T PL 15827671T PL 3179982 T3 PL3179982 T3 PL 3179982T3
Authority
PL
Poland
Prior art keywords
prolonging
bioavailability
drug
increasing
ophthalmic
Prior art date
Application number
PL15827671.7T
Other languages
English (en)
Inventor
Ajay Jaysingh Khopade
Arindam Halder
Original Assignee
Sun Pharma Advanced Research Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Company Ltd filed Critical Sun Pharma Advanced Research Company Ltd
Publication of PL3179982T3 publication Critical patent/PL3179982T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts or implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5176Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/16Organic material
    • B01J39/18Macromolecular compounds
    • B01J39/20Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15827671.7T 2014-07-28 2015-07-24 Sposób zwiększenia biodostępności i/lub przedłużenia działania oftalmicznego leku PL3179982T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2437MU2014 2014-07-28
IN2206MU2015 2015-06-09
PCT/IN2015/050076 WO2016016908A1 (en) 2014-07-28 2015-07-24 Method of increasing bioavailability and/or prolonging ophthalmic action of a drug

Publications (1)

Publication Number Publication Date
PL3179982T3 true PL3179982T3 (pl) 2023-09-25

Family

ID=55216857

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15827671.7T PL3179982T3 (pl) 2014-07-28 2015-07-24 Sposób zwiększenia biodostępności i/lub przedłużenia działania oftalmicznego leku

Country Status (6)

Country Link
US (5) US10172852B2 (pl)
EP (2) EP3179982B1 (pl)
JP (1) JP6567648B2 (pl)
ES (1) ES2951202T3 (pl)
PL (1) PL3179982T3 (pl)
WO (1) WO2016016908A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3179982B1 (en) 2014-07-28 2023-07-19 Sun Pharma Advanced Research Company Ltd Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
EP3470059B1 (en) 2015-01-26 2020-04-01 Bausch & Lomb Incorporated Ophthalmic suspension composition
EP3328361B1 (en) * 2015-07-27 2021-09-15 Sun Pharma Advanced Research Company Ltd Drug loaded nanoresin particles
US10020844B2 (en) 2016-12-06 2018-07-10 T&T Intellectual Property I, L.P. Method and apparatus for broadcast communication via guided waves
US11241443B2 (en) 2017-04-07 2022-02-08 Sun Pharma Advanced Research Company Ltd. Ophthalmic solution of bimatoprost
JP7170436B2 (ja) * 2017-06-28 2022-11-14 千寿製薬株式会社 水溶性高分子を含む点眼剤
JP6621955B2 (ja) * 2018-03-30 2019-12-18 千寿製薬株式会社 水性液剤
JP6653037B2 (ja) * 2018-03-30 2020-02-26 千寿製薬株式会社 水性液剤
AU2019315509B2 (en) 2018-07-31 2025-06-26 Microbion Corporation Bismuth-thiol compositions and methods of use
AU2019312592B2 (en) 2018-07-31 2025-06-26 Microbion Corporation Bismuth-thiol compositions and methods for treating wounds
JP2020033290A (ja) * 2018-08-29 2020-03-05 興和株式会社 水性組成物
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤
US11564909B2 (en) * 2020-11-30 2023-01-31 Romeg Therapeutics Llc Methods and compositions for oral pilocarpine liquid
WO2022153208A1 (en) * 2021-01-13 2022-07-21 Sun Pharma Advanced Research Company Limited Method of reducing elevated intraocular pressure
US20240041869A1 (en) * 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Ophthalmic composition comprising an anti-allergen and a redness reduction agent
CA3264067A1 (en) * 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited OPHTHALMIC COMPOSITION COMPRISING PILOCARPINE AND A REDNESS-REDUCING AGENT

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0725698B2 (ja) * 1984-10-31 1995-03-22 アルコン ラボラトリーズ インコーポレイテッド 持続的放出性を有し快適に適用できる緑内障治療用の処方物
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
DE3722837A1 (de) * 1987-07-10 1989-01-19 Ruetgerswerke Ag Ophthalmisches depotpraeparat
US5275820A (en) 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5296228A (en) 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
EP0995435B1 (en) 1997-05-14 2007-04-25 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
BR9913955A (pt) * 1998-09-25 2001-06-12 Alcon Lab Inc Composição oftalmológica confortável e de liberação sustentada e método para terapia ocular
US6258350B1 (en) * 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
AU4338700A (en) 1999-05-12 2000-12-05 Alcon Laboratories, Inc. Use of polymeric adsorbents in pharmaceutical dosage forms
US7001615B1 (en) * 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
KR100990810B1 (ko) * 2001-12-21 2010-10-29 알콘, 인코퍼레이티드 안과용 약물 및 이과용 약물을 위한 담체로서 합성 무기 나노입자의 용도
BRPI0506983A (pt) * 2004-01-20 2007-07-03 Allergan Inc composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico
US20050238695A1 (en) * 2004-04-27 2005-10-27 Atma Chaudhari Lozenge for delivery of dextromethorphan
WO2008033924A2 (en) * 2006-09-12 2008-03-20 Board Of Regents Of The University Of Nebraska Methods and compositions for targeted delivery of therapeutic agents
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
JP2013531044A (ja) 2010-07-15 2013-08-01 コリンシアン オフサルミック,インコーポレイティド 点眼薬送達
HK1208161A1 (en) * 2012-05-03 2016-02-26 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
EP3179982B1 (en) * 2014-07-28 2023-07-19 Sun Pharma Advanced Research Company Ltd Method of increasing bioavailability and/or prolonging ophthalmic action of a drug

Also Published As

Publication number Publication date
US20210308130A1 (en) 2021-10-07
US20170239243A1 (en) 2017-08-24
US12409175B2 (en) 2025-09-09
EP3179982A1 (en) 2017-06-21
US20190070176A1 (en) 2019-03-07
JP6567648B2 (ja) 2019-08-28
US11931359B2 (en) 2024-03-19
US20240180902A1 (en) 2024-06-06
ES2951202T3 (es) 2023-10-19
EP3179982A4 (en) 2017-12-27
US11058684B2 (en) 2021-07-13
US10172852B2 (en) 2019-01-08
WO2016016908A1 (en) 2016-02-04
JP2017525686A (ja) 2017-09-07
US11951106B2 (en) 2024-04-09
US20230098352A1 (en) 2023-03-30
EP3954362A1 (en) 2022-02-16
EP3179982B1 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
NL301322I2 (nl) Repotrectinib en/of farmaceutisch aanvaardbare zouten daarvan
PL3179982T3 (pl) Sposób zwiększenia biodostępności i/lub przedłużenia działania oftalmicznego leku
IL258931A (en) Therapeutic compounds and methods
IL248757A0 (en) Controllable drug delivery system and method of use
LT3212189T (lt) Pakeisti chromanai ir naudojimo būdas
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
HUE066468T2 (hu) Idegnyugtató norketamin vegyületek és eljárások
HUE046000T2 (hu) Antiproferatív vegyületek és alkalmazásuk módszerei
EP3205103C0 (en) INTER AND INTRA UNIFICATION BLOCK COPY
PT3548033T (pt) Compostos e respectivos métodos de utilização
EP3328333A4 (en) SYSTEMS AND METHODS FOR CORNEAL IMPLANTS
IL252172A0 (en) Expandable drug delivery devices and method of use
EP3970906C0 (en) LASER ABLATION AND TREATMENT METHODS AND SYSTEMS
HUE056287T2 (hu) Pancreatitis kezelése
EP3551036A4 (en) STIMULUS AND EYE TRACKING SYSTEM
PT3319612T (pt) Oxisteróis e métodos de utilização dos mesmos
EP3528737A4 (en) MEDICAL SUPPORT
IL253889A0 (en) Detection of brain injury
PL3457851T3 (pl) Pochodne sobetiromu
IL251167A0 (en) Cytotoxic and anti-mitotic compounds, and methods of using the same
BR112016025413A2 (pt) método de fabricação de um inserto e inserto
EP3639617A4 (en) RAN ZONE ID CONFIGURATION
FR3059559B1 (fr) Descendeur autobloquant
DK3137873T3 (da) Viscometer and methods of use thereof
EP3437644A4 (en) MEDICINE